SEPN
Septerna, Inc.
NASDAQ · Healthcare · Biotechnology · US
$36.38
+0.08%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$36.48
From 52W high−24.51%
Volume410189.00
Market cap$1.70B
P/E (TTM)—
P/S (TTM)17.2x
Div yield—
Key dataOct 19, 2026
Open
$36.48
From 52W high
−24.51%
Volume
410189.00
Market cap
$1.70B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−34.3x
P/E (TTM)
—
RSI (14)
48.4
MomentumView details →
1D Return
+0.08%
YTD Return
+34.04%
SummaryUpdated Jun 1, 2026
Septerna, Inc. (NASDAQ:SEPN) is a clinical-stage biotechnology company founded in 2019 and headquartered in South San Francisco, California. Originally incorporated as GPCR NewCo, Inc., the company changed its name to Septerna Inc. in June 2021 and went public in October 2024. Septerna focuses on discovering and developing oral small molecule drug candidates that target G protein-coupled receptors (GPCRs) for treating endocrinology, immunology, inflammation, and metabolic diseases.
Similar companies
Latest newsMore news →
RA Capital Management, L.P., a significant shareholder and director of Septerna, Inc., sold 1,493,000 shares of Septerna common stock for $63,452,500 on August 12, 2026.66d agoSepterna, Inc. reported a second-quarter net loss of $0.29 per share, beating the Zacks Consensus Estimate of a $0.48 loss and improving from a $0.56 loss a year earlier.70d ago